Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedJun 06, 2026
DataAggregated Company Financials
Companies145
  • 7D-0.6%
  • 3M11.0%
  • 1Y-2.2%
  • YTD5.3%

Over the last 7 days, the Healthcare industry has remained flat, although notably Sectra gained 5.3%. Furthermore, the industry has been flat for the past year as well. Earnings are forecast to grow by 27% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 06 Jun 2026SEK 617.7bSEK 229.1b-SEK 3,335,253,711.4335.1x-185.2x2.7x
Mon, 04 May 2026SEK 592.3bSEK 228.8b-SEK 1,861,238,789.1331.7x-318.2x2.6x
Wed, 01 Apr 2026SEK 560.4bSEK 229.0b-SEK 2,927,187,557.0230.4x-191.4x2.4x
Fri, 27 Feb 2026SEK 575.6bSEK 229.2b-SEK 1,620,513,611.8132.6x-355.2x2.5x
Sun, 25 Jan 2026SEK 598.2bSEK 257.5bSEK 5.6b40x106.7x2.3x
Tue, 23 Dec 2025SEK 584.8bSEK 230.6bSEK 3.7b43.3x160.2x2.5x
Thu, 20 Nov 2025SEK 583.9bSEK 230.5bSEK 2.9b44.8x200.7x2.5x
Sat, 18 Oct 2025SEK 601.1bSEK 227.1bSEK 6.7b42.6x90x2.6x
Mon, 15 Sep 2025SEK 613.4bSEK 227.0bSEK 6.6b45.5x93x2.7x
Wed, 13 Aug 2025SEK 609.2bSEK 226.8bSEK 6.6b46.9x92.2x2.7x
Fri, 11 Jul 2025SEK 642.1bSEK 226.7bSEK 6.0b44.9x106.7x2.8x
Sun, 08 Jun 2025SEK 630.5bSEK 226.5bSEK 5.8b43.8x107.9x2.8x
Tue, 06 May 2025SEK 599.2bSEK 223.6bSEK 4.9b36.9x122x2.7x
Thu, 03 Apr 2025SEK 567.4bSEK 220.7bSEK 5.4b35.6x105x2.6x
Sat, 01 Mar 2025SEK 584.8bSEK 206.2bSEK 4.3b35.8x136.4x2.8x
Mon, 27 Jan 2025SEK 583.0bSEK 202.6b-SEK 2,675,705,168.5040.6x-217.9x2.9x
Wed, 25 Dec 2024SEK 577.8bSEK 202.7b-SEK 2,503,854,548.6138.4x-230.7x2.8x
Fri, 22 Nov 2024SEK 499.6bSEK 200.0b-SEK 2,721,737,001.2737x-183.6x2.5x
Sun, 20 Oct 2024SEK 599.2bSEK 198.9b-SEK 3,204,651,387.2939.4x-187x3x
Tue, 17 Sep 2024SEK 621.9bSEK 200.0b-SEK 2,795,395,233.1741.7x-222.5x3.1x
Thu, 15 Aug 2024SEK 581.7bSEK 199.9b-SEK 2,561,710,497.7941.5x-227.1x2.9x
Sat, 13 Jul 2024SEK 585.4bSEK 196.1b-SEK 3,117,178,694.3238.3x-187.8x3x
Mon, 10 Jun 2024SEK 564.1bSEK 195.9b-SEK 3,147,692,207.7736.4x-179.2x2.9x
Wed, 08 May 2024SEK 543.6bSEK 196.6b-SEK 3,070,655,585.5035.6x-177x2.8x
Fri, 05 Apr 2024SEK 525.1bSEK 192.9b-SEK 3,320,820,680.8445.9x-158.1x2.7x
Sun, 03 Mar 2024SEK 512.0bSEK 192.0b-SEK 3,663,022,021.3645.1x-139.8x2.7x
Tue, 30 Jan 2024SEK 554.0bSEK 191.6b-SEK 892,587,250.0049.3x-620.7x2.9x
Thu, 28 Dec 2023SEK 539.0bSEK 191.0b-SEK 960,479,695.0047.5x-561.1x2.8x
Sat, 25 Nov 2023SEK 501.3bSEK 190.0b-SEK 1,225,557,640.0050.2x-409x2.6x
Mon, 23 Oct 2023SEK 422.0bSEK 185.5b-SEK 1,926,276,118.0031.5x-219.1x2.3x
Wed, 20 Sep 2023SEK 442.5bSEK 185.7b-SEK 1,987,704,802.0035.1x-222.6x2.4x
Fri, 18 Aug 2023SEK 460.1bSEK 184.3b-SEK 1,028,536,507.0040.2x-447.4x2.5x
Sun, 16 Jul 2023SEK 465.5bSEK 179.6b-SEK 866,115,788.0044.4x-537.5x2.6x
Tue, 13 Jun 2023SEK 522.4bSEK 179.0b-SEK 766,462,280.0042.8x-681.5x2.9x
Price to Earnings Ratio

-681.5x


Total Market Cap: SEK 522.4bTotal Earnings: -SEK 766,462,280.00Total Revenue: SEK 179.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -144.9x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 8.6% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market-1.09%
Healthcare-0.57%
Healthtech4.23%
Pharma2.72%
Life Sciences0.62%
Medical Equipment0.11%
Biotech-2.18%
Healthcare Services-2.39%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 125x.
    • Analysts are expecting annual earnings growth of 23.3%, which is higher than its past year's earnings growth of 0.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 37% over the next 5 years.
  • This is better than its past earnings decline of 11% per year.
  • In contrast, the Healthcare Services industry is expected to see its earnings grow by 18% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SECT B SectraSEK 293.005.3%
+SEK 2.9b		-17.4%PE100.1x
SOBI Swedish Orphan BiovitrumSEK 446.601.0%
+SEK 1.5b		45.4%PE167.7x
CAMX CamurusSEK 547.504.0%
+SEK 1.3b		-14.3%PE48x
GETI B GetingeSEK 194.352.4%
+SEK 1.2b		2.5%PE22.4x
EKTA B ElektaSEK 55.303.0%
+SEK 611.3m		10.7%PS1.3x

Latest News

SECT B
SEK 293.00
Sectra
7D
5.3%
1Y
-17.4%
XSPRAY
SEK 17.80
Xspray Pharma
7D
-28.8%
1Y
-43.1%
ATT
SEK 113.00
Attendo
7D
-4.2%
1Y
80.8%
AMBEA
SEK 141.60
Ambea
7D
-5.8%
1Y
26.3%
Narrative Update • Jun 04

AMBEA: Nordic Care Acquisitions And Dividend Will Drive Future Upside Potential

Analysts now see Ambea’s fair value at SEK 181.0 per share, with a slightly higher discount rate and a lower future P/E assumption. Together these factors explain the unchanged price target despite refined model inputs.
GETI B
SEK 194.35
Getinge
7D
2.4%
1Y
2.5%
CAMX
SEK 547.50
Camurus
7D
4.0%
1Y
-14.3%
Narrative Update • Jun 03

CAMX: Expanded Cardiometabolic Partnership Will Support Further Share Price Upside

Analysts have adjusted their price target on Camurus to SEK 914 from SEK 930. This change reflects updated views on growth, profitability, a slightly higher discount rate, and expectations for a lower future P/E multiple.
SOBI
SEK 446.60
Swedish Orphan Biovitrum
7D
1.0%
1Y
45.4%
CURAS
DKK 24.00
Curasight
7D
29.7%
1Y
939.0%
VITR
SEK 96.15
Vitrolife
7D
-2.8%
1Y
-38.9%
Narrative Update • Jun 01

VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential

Analysts have trimmed their price target on Vitrolife to SEK162.75 from SEK172.20, citing slightly higher discount rate assumptions, more cautious revenue growth expectations, softer profit margin estimates, and a modestly lower future P/E multiple following recent bearish Street research, including a downgrade from Pareto. What's in the News CEO Bronwyn Brophy O'Connor has resigned to take a CEO role elsewhere in the medtech industry, and the Board has started a recruitment process for a new CEO.
BIOA B
SEK 308.00
BioArctic
7D
-12.6%
1Y
53.1%
Narrative Update • Jun 01

BIOA B: Alzheimer’s Access Delays And Nordic Rollout Will Shape Future Returns

Analysts now set their fair value estimate for BioArctic at SEK 363, down slightly from SEK 367. This reflects updated assumptions around revenue growth, profit margins and a lower future P/E multiple.
EKTA B
SEK 55.30
Elekta
7D
3.0%
1Y
10.7%
Narrative Update • Jun 01

EKTA B: Transformation Progress And Cost Savings Will Support Medium Term Upside

Analysts have lifted their fair value estimate for Elekta from about SEK 87 to roughly SEK 93. This reflects updated assumptions around discount rates, revenue growth, margins and a higher future P/E, even as recent Street research has shifted the stock toward more Hold-oriented ratings with price targets around SEK 58 to SEK 60.
IMP A SDB
SEK 56.10
Implantica
7D
-6.7%
1Y
30.8%
BIOG B
SEK 122.10
BioGaia
7D
-6.3%
1Y
18.2%
Narrative Update • May 24

BIOG B: Margin Resilience And LongevityGuard Technology Will Support Future Re Rating

The updated analyst price target for BioGaia has moved from SEK 140 to SEK 165, with analysts pointing to adjusted assumptions around revenue growth, profit margins, and future P/E expectations, even as some recent research has turned more cautious on the stock. Analyst Commentary Analyst views on BioGaia are mixed, with some focusing on the higher SEK 165 price target and others turning more cautious after recent research updates.
CEVI
SEK 126.00
CellaVision
7D
4.5%
1Y
-35.1%
Narrative Update • May 24

CEVI: Bone Marrow Expansion And Steady Margins Will Support Future Upside

Analysts now keep their SEK price target for CellaVision effectively unchanged at around SEK 179. This reflects only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions rather than a shift in their overall view of the stock.
ASKER
SEK 81.65
Asker Healthcare Group
7D
-1.6%
1Y
-23.4%
ALIF B
SEK 152.30
AddLife
7D
2.3%
1Y
-20.6%